Inventurus Knowledge Solutions Limited — Investor Meet, 06-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

IKS Health reported robust financial results for the quarter and half-year. Revenue hit ₹781 Cr, up 22% YoY (17% in USD constant currency), with EBITDA at ₹272 Cr (35% margin) and PAT at ₹181 Cr. This strong bottom-line growth (EBITDA +43% YoY, PAT +60% YoY) is fueled by AI integration and AQuity operational transformation, achieving target margins ahead of schedule. The company sees strong interest in its outcome-oriented platform deals, actively expanding its client base, and focusing on ~50 enterprise customers for future growth, backed by disciplined capital allocation. Management is confident in the large, untapped US healthcare market opportunity.